

August 2017

RE: Change in salt of Decapeptyl® SR (triptorelin) 11.25mg powder and solvent for suspension for injection. PL 34926/0003

Dear Healthcare Professional,

We are writing to inform you of an active ingredient change for our product Decapeptyl® SR (triptorelin) 11.25mg powder and solvent for suspension for injection.

The active ingredient in the product is changing from a triptorelin acetate to a triptorelin pamoate.

Decapeptyl® SR (triptorelin) 11.25mg is licensed for:

- Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration.
- Treatment of metastatic prostate cancer.
- As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
- As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer.
- As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression.
- Treatment of endometriosis.
- Treatment of precocious puberty (onset before 8 years in girls and 10 years in boys).

There are no changes needed to the dose or administration method, and the contraindications, special warnings and precautions for use in the summary of product characteristics remain the same.

The new pamoate stock will enter the UK supply chain from mid-August. We will do our utmost to avoid any cross-over or confusion in the supply chain, but there may be a brief period where both packs could be supplied to healthcare professionals.

For any questions or concerns you may have, please contact our Medical Information Department via the phone or email details stated below.

Healthcare professionals are asked to report any suspected adverse reactions to medicines via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard

Ipsen Ltd Medical Information Department Contact Details:

Phone: 01753 627 777

Email: medical.information.uk@ipsen.com

Yours sincerely,



Matthew Hickling
Medical Director

TRI-UK-002733 June 2017

RMS18968